As Sanofi and Regeneron await the FDA decision, a legal dispute between the partners over commercialisation details continues ...

Shortly after we made a diagnosis of bullous pemphigoid in this minipig, we found that a second minipig in the colony had similar, but less severe, lesions. Again, we did not administer ...

The supplemental biologics license application for Dupixent for the treatment of bullous pemphigoid in adults ... is driven by type 2 inflammation which causes blisters and rashes to form on ...

Patients treated with on dupilumab showed significant improvement in sustained BP remission compared with those on placebo.

Dupilumab, an interleukin-4 receptor antagonist, is expected to decrease the type 2 inflammation seen in bullous pemphigoid.

Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoidIf approved, Dupixent would be the first and only ...

US FDA accepts for priority review Sanofi & Regeneron’s Dupixent sBLA for the targeted treatment of bullous pemphigoid: Paris Wednesday, February 19, 2025, 12:00 Hrs [IST] The U ...

Paris: Sanofi has announced that the US Food and Drug Administration (FDA) has accepted for priority review the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to ...

Sanofi and Regeneron’s blockbuster biologic Dupixent (dupilumab) is poised for yet another label expansion, this time for the rare autoimmune skin disorder bullous pemphigoid (BP). The US Food ...

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025Priority ...